<p>PureTech Health PLC 贊助的 ADR (NASDAQ:PRTC - 獲取免費報告) 在三月份的空頭頭寸大幅增加。截至 3 月 31 日，空頭頭寸總計為 14,823 股，比 3 月 15 日的 11,335 股增加了 30.8%。根據每日平均交易量 3,250 股，目前的空頭頭寸比率為 4.6 天。公司約有 0.1% 的股份被做空。</p>
<p>獲取 <strong>PureTech Health</strong> 的提醒：</p>
<h2>對 PureTech Health 的對沖基金看法</h2>
<p>一家對沖基金最近增加了對 PureTech Health 股票的持股。根據該公司在最近向 SEC 提交的 13F 文件，Pentwater Capital Management LP 在第三季度將其在 PureTech Health PLC 贊助的 ADR (NASDAQ:PRTC - 免費報告) 的持股增加了 50.0%。該機構投資者在季度內購買了額外的 25,000 股後，持有 75,000 股公司的股票。根據其最近向 SEC 提交的文件，Pentwater Capital Management LP 持有的 PureTech Health 股票價值為 1,388,000 美元，佔公司股份的 0.31%。機構投資者持有公司 0.04% 的股票。</p>
<h2>華爾街分析師預測增長</h2>
<p>另外，Weiss Ratings 在 1 月 22 日的報告中重申了對 PureTech Health 股票的 &#34;賣出 (d)&#34; 評級。根據 MarketBeat.com 的數據，一名股票研究分析師對該股票給予了賣出評級，目前該公司的平均評級為 &#34;賣出&#34;。</p>
<p><strong>查看我們關於 PureTech Health 的最新報告</strong></p>
<h2>PureTech Health 股票上漲 2.0%</h2>
<p>週三，PRTC 股票上漲 0.36 美元，達到 18.23 美元。該股票交易了 3,250 股，較其平均交易量 4,112 股有所減少。PureTech Health 的 52 周低點為 14.50 美元，52 周高點為 19.92 美元。該公司的 50 日移動平均價格為 16.86 美元，200 日移動平均價格為 17.29 美元。</p>
<h2>關於 PureTech Health</h2>
<p>(獲取免費報告)</p>
<p>PureTech Health NASDAQ: PRTC 是一家臨牀階段的生物治療公司，專注於在免疫學、炎症、腫瘤學和神經科學領域創造和開發首創藥物。該公司通過在內部孵化項目並將選定資產推進為獨立的、創造價值的實體來運營。其內部管道包括多個針對纖維化疾病、實體腫瘤和罕見遺傳疾病的臨牀和臨牀前候選藥物。</p>
<p>PureTech 的專有平台技術涵蓋單克隆抗體、小分子和細胞治療等多種形式。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 PureTech Health</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 PureTech Health 嗎？</h2>
<p>在你考慮 PureTech Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買... 而 PureTech Health 並不在名單上。</p>
<p>雖然 PureTech Health 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

PRTC

PRTCY

<p>PureTech Health PLC 贊助的 ADR (NASDAQ:PRTC) 在三月份經歷了空頭頭寸的顯著增加，上漲了 30.8%，達到 14,823 股。這代表了公司被賣空股份的 0.1%，根據平均每日交易量 3,250 股，覆蓋天數比率為 4.6 天。機構投資者 Pentwater Capital Management LP 在第三季度將其持股增加了 50%。分析師對該股票維持 “賣出” 評級，目前交易價格為 18.23 美元，上漲 2.0%</p>

<p>PureTech Health PLC Sponsored ADR (NASDAQ:PRTC - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totaling 14,823 shares, an increase of 30.8% from the March 15th total of 11,335 shares. Based on an average daily volume of 3,250 shares, the short-interest ratio is currently 4.6 days. Approximately 0.1% of the shares of the company are short sold.</p>
<div class="lb-trans"><p>PureTech Health PLC 贊助的 ADR (NASDAQ:PRTC - 獲取免費報告) 在三月份的空頭頭寸大幅增加。截至 3 月 31 日，空頭頭寸總計為 14,823 股，比 3 月 15 日的 11,335 股增加了 30.8%。根據每日平均交易量 3,250 股，目前的空頭頭寸比率為 4.6 天。公司約有 0.1% 的股份被做空。</p>
</div><p>Get <strong>PureTech Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>PureTech Health</strong> 的提醒：</p>
</div><h2>Hedge Funds Weigh In On PureTech Health</h2>
<div class="lb-trans"><h2>對 PureTech Health 的對沖基金看法</h2>
</div><p>A hedge fund recently raised its stake in PureTech Health stock. Pentwater Capital Management LP grew its holdings in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC - Free Report) by 50.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 75,000 shares of the company's stock after buying an additional 25,000 shares during the quarter. Pentwater Capital Management LP owned 0.31% of PureTech Health worth $1,388,000 as of its most recent filing with the SEC. Institutional investors own 0.04% of the company's stock.</p>
<div class="lb-trans"><p>一家對沖基金最近增加了對 PureTech Health 股票的持股。根據該公司在最近向 SEC 提交的 13F 文件，Pentwater Capital Management LP 在第三季度將其在 PureTech Health PLC 贊助的 ADR (NASDAQ:PRTC - 免費報告) 的持股增加了 50.0%。該機構投資者在季度內購買了額外的 25,000 股後，持有 75,000 股公司的股票。根據其最近向 SEC 提交的文件，Pentwater Capital Management LP 持有的 PureTech Health 股票價值為 1,388,000 美元，佔公司股份的 0.31%。機構投資者持有公司 0.04% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Separately, Weiss Ratings restated a &#34;sell (d)&#34; rating on shares of PureTech Health in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 1 月 22 日的報告中重申了對 PureTech Health 股票的 &#34;賣出 (d)&#34; 評級。根據 MarketBeat.com 的數據，一名股票研究分析師對該股票給予了賣出評級，目前該公司的平均評級為 &#34;賣出&#34;。</p>
</div><p><strong>Check Out Our Latest Report on PureTech Health</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 PureTech Health 的最新報告</strong></p>
</div><h2>PureTech Health Trading Up 2.0%</h2>
<div class="lb-trans"><h2>PureTech Health 股票上漲 2.0%</h2>
</div><p>PRTC traded up $0.36 on Wednesday, hitting $18.23. 3,250 shares of the stock traded hands, compared to its average volume of 4,112. PureTech Health has a 52 week low of $14.50 and a 52 week high of $19.92. The business has a fifty day moving average price of $16.86 and a two-hundred day moving average price of $17.29.</p>
<div class="lb-trans"><p>週三，PRTC 股票上漲 0.36 美元，達到 18.23 美元。該股票交易了 3,250 股，較其平均交易量 4,112 股有所減少。PureTech Health 的 52 周低點為 14.50 美元，52 周高點為 19.92 美元。該公司的 50 日移動平均價格為 16.86 美元，200 日移動平均價格為 17.29 美元。</p>
</div><h2>About PureTech Health</h2>
<div class="lb-trans"><h2>關於 PureTech Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>PureTech Health NASDAQ: PRTC is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.</p>
<div class="lb-trans"><p>PureTech Health NASDAQ: PRTC 是一家臨牀階段的生物治療公司，專注於在免疫學、炎症、腫瘤學和神經科學領域創造和開發首創藥物。該公司通過在內部孵化項目並將選定資產推進為獨立的、創造價值的實體來運營。其內部管道包括多個針對纖維化疾病、實體腫瘤和罕見遺傳疾病的臨牀和臨牀前候選藥物。</p>
</div><p>PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.</p>
<div class="lb-trans"><p>PureTech 的專有平台技術涵蓋單克隆抗體、小分子和細胞治療等多種形式。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than PureTech Health</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 PureTech Health</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in PureTech Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 PureTech Health 嗎？</h2>
</div><p>Before you consider PureTech Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 PureTech Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買... 而 PureTech Health 並不在名單上。</p>
</div><p>While PureTech Health currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 PureTech Health 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

PureTech Health PLC 贊助的美國存託憑證（NASDAQ:PRTC）在三月份的空頭頭寸增加了 30.8%